Dynamic changes in 18F-borono-L-phenylalanine uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck and malignant melanoma during boron neutron capture therapy patient selection
Radiation Oncologyvolume 13, Article number: 4 (2018)
We evaluated dynamic changes in 18F–borono-L-phenylalanine (18F–BPA) uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck (SCC) and malignant melanoma (MM) during boron neutron capture therapy (BNCT) patient selection.
Dynamic changes in the maximum standardized uptake value (SUVmax), tumor-to-normal tissue ratio (TNR), and tumor-to-blood pool ratio (TBR) for 18F–BPA were evaluated in 20 patients with SCC and 8 patients with MM.
SUVmax in SCC tumors decreased significantly from 30 to 120 min. There was a non-statistically significant decrease in SUVmax for SCC tumors from 30 to 60 min and from 60 to 120 min. Patients with MM had nonsignificant SUVmax changes in 18F–BPA uptake on delayed imaging. Nonsignificant 18F–BPA TNR and TBR changes were seen in patients with SCC and MM.
Dynamic changes in SUVmax for 18F–BPA uptake had a washout pattern in SCC and a persistent pattern in MM. Dynamic 18F–BPA -PET studies should be performed to investigate the pharmacokinetics of 18F–BPA in humans and select appropriate candidates who may benefit from BNCT.
Boron neutron capture therapy (BNCT) has been used for various types of intractable cancers, including glioblastoma, head and neck tumors, and melanoma [1,2,3,4,5,6]. This type of radiation therapy is based on nuclear reactions between neutrons and boron-10 (10B). After a targeted tumor contains a considerable concentration of 10B, the region to be treated is exposed to thermal neutrons. The nuclear reactions between these neutrons and 10B produce alpha particles and 7Li in a very short range (<10 μm) that should kill the cell. The success of BNCT depends on sufficient accumulation of 10B in tumor cells relative to adjacent tissues [5, 6]. Therefore, it is necessary to assess 10B concentration in tumor tissue before BNCT is performed .
Positron emission tomography (PET) using 18F–borono-L-phenylalanine (18F–BPA) has been used to screen for appropriate candidates who can benefit from BNCT [2, 3, 8,9,10,11]. Before BNCT, the 10B concentration in tumor tissue is estimated by measuring the tumor-to-normal tissue ratio (TNR) and the tumor-to-blood pool ratio (TBR) with 18F–BPA PET imaging [2, 3, 12, 13]. Hanaoka et al. demonstrated a significant positive correlation between levels of BPA and 18F–BPA accumulation in an animal model . 10B accumulation is not consistent across patients; it is reported to also depend on tumor type [15, 16]. Thus, knowledge of the dynamic changes in 10B accumulation by tumor type is critical for performing BNCT. However, there is still limited information in the literature regarding dynamic changes in 18F–BPA uptake in various tumor types in humans. The purpose of this study was to examine the dynamic changes in the maximum standardized uptake value (SUVmax) of 18F–BPA in squamous cell carcinoma of the head and neck (SCC) and malignant melanoma (MM). TNR and TBR of 18F–BPA in SCC and MM were also evaluated.
The study protocol was approved by the institutional review board and independent ethics committee of our hospital. All patients provided written informed consent before inclusion in the trial.
Radiosynthesis of 18F–BPA
18F–BPA was synthesized with direct electrophilic radiofluorination of BPA (Sigma-Aldrich, St. Louis, MO, USA) using 18F–acetyl hypofluorite as described previously [7, 17]. Purification of 18F–BPA was performed by high performance liquid chromatography (HPLC) using a YMC-Pack ODS-A column (20 × 150 mm; YMC, Kyoto, Japan) eluted with 0.1% acetic acid at a flow rate of 10 mL/min. The radiochemical purity of 18F–BPA as determined by HPLC was >99.5%. Its specific activity was 25 MBq/μmol.
Patients and PET/CT protocol
This study included 20 patients with SCC and 8 patients with MM who underwent 18F–BPA PET/CT from March 2012 to August 2016. Patients had histologically confirmed malignant tumors and an Eastern Cooperative Oncology Group performance status of 0–1. We defined adequate organ function for patients with unresectable cancer on the basis of the normal range observed by our hospital laboratory. Adequate organ function was determined by neutrophil count ≥1500 /μL, platelet count ≥75,000 /μL, hemoglobin ≥9.0 g/dL, serum bilirubin ≤1.5 mg/dL, aspartate transaminase (AST) ≤ 100 IU/L, alanine aminotransferase (ALT) ≤ 100 IU/L, serum creatinine ≤1.5 mg/dL, and baseline left ventricular ejection fraction >60%. The main exclusion criteria were congestive heart failure, uncontrolled angina pectoris, arrhythmia, symptomatic infectious disease, severe bleeding, pulmonary fibrosis, obstructive bowel disease or severe diarrhea, and symptomatic pleural or pericardial effusion. This study was approved by the ethics committees of our institution.
Dynamic changes in 18F–BPA uptake were evaluated in 20 patients with SCC and 8 patients with MM. PET images were acquired using a Discovery 600 scanner (GE Healthcare, Milwaukee, WI, USA). PET images were reconstructed as using a 3D ordered-subset expectation maximization algorithm. PET image evaluation and quantification of SUV were performed using AW Volume Share 4.5 software. SUV was defined as regional radioactivity divided by injected radioactivity normalized to body weight. PET/CT images were taken 30, 60, and 120 min after 18F–BPA injection (4.0 MBq/kg of body weight). Regions of interest (ROIs) were drawn on the reconstructed PET images. Tumor SUVmax in ROIs was defined as the area of highest activity. ROIs were also drawn around normal tissue surrounding the tumor to calculate the TNR for 18F–BPA and the blood pool in order to calculate the TBR for 18F–BPA. The retention index (RI) was defined as the difference in SUVmax between early and delayed 18F–BPA PET imaging, expressed as a percentage of the initial uptake (RI = (SUVdelayed − SUVearly)/SUVearly × 100%). The difference in SUVmax and RI were calculated to evaluate the change in tracer levels in malignant lesions at 30, 60 and 120 min after 18F–BPA injection. Quantitative values above zero were defined as increased SUVmax and values below zero were defined as decreased SUVmax.
SUVmax, TNR, and TBR were analyzed using paired one-way ANOVA. The paired t-test was used to determine the significance of differences in dynamic SUVmax values, TNR, and TBR. P < 0.05 was considered to indicate a statistically significant difference. For statistical analysis, JMP software (version 11.0, SAS Institute, Inc., Cary, NC, USA) was used.
Patient characteristics are summarized in Table 1. SUVmax, TNR, and TBR for 18F–BPA in SCC and MM are summarized in Table 2. Only SUVmax showed significant differences between 30 and 120 min in patients with SCC.
Figure 1 is a box plot of SUVmax for tumors at 30, 60, and 120 min after injection. SUVmax in SCC tumors decreased significantly from 30 to 120 min, but the decrease was not statistically significant from 30 to 60 min and from 60 to 120 min. All 20 patients with SCC had gradual decreases in SUVmax from 30 to 120 min (Table 2). On the other hand. Nonsignificant 18F–BPA differences on delayed imaging were seen in patients with MM (Fig. 1, Tables 2 and 3). In contrast to patients with SCC, not all patients with MM had decreases in SUVmax from 30 to 60 min, 60 to 120 min, and 30 to 120 min.
The aim of this study was to examine dynamic 18F–BPA changes in SUVmax in SCC and MM as part of the patient selection process for BNCT. In SCC, dynamic changes in SUVmax for 18F–BPA uptake had a washout pattern, compared with a persistent pattern of 18F–BPA uptake in MM.
18F–BPA was developed to predict 10B accumulation in tumors and normal tissues with PET . Studies have shown that there are a variety of amino acid transporters, such as Systems L, A, ASC, and B [19, 20]. System L is the primary contributor to 18F–BPA uptake, which is correlated with total L-amino acid transporter (LAT) expression, more specifically LAT1 and LAT4. Many tumors overexpress LAT1 or LAT4 [21,22,23]. Previous studies have shown that the expression of amino acid transporters in tumors varies widely, and it sometimes reflects proliferation speed and malignancy . However, reasons for differences in dynamic changes in 18F–BPA uptake between SCC and MM remain uncertain. It is unclear whether 18F–BPA undergoes metabolic transformation, although metabolic transformation of L-phenylalanine has been reported . LAT and the metabolic transformation of 18F–BPA may contribute to dynamic changes in 18F–BPA accumulation in tumors. Further studies with more participants and evaluation of processes involved in 18F–BPA metabolic transformation are needed to resolve this question.
In clinical BNCT, 18F–BPA accumulation was measured about 1 h after 18F–BPA administration [26,27,28,29]. However, the number of dynamic studies of 18F–BPA uptake in humans is limited. Therefore, we focused on dynamic 18F–BPA uptake in humans. Our study showed that SUVmax for 18F–BPA uptake in SCC has a washout pattern. It is very important to realize that some tumor histological types may have a washout pattern. 18F–BPA uptake in different tumor types may be vary with extended distribution time in 18F–BPA PET imaging. Further dynamic 18F–BPA -PET studies should be performed to determine who are appropriate candidates that can benefit from BNCT.
In this study, we did not evaluate the pharmacokinetics of BPA or the BPA-fructose complex because we focused on dynamic accumulation of 18F–BPA in human tumors. Hanaoka et al. showed a positive association between the levels of BPA and 18F–BPA accumulation in a rat model . However, the biodistribution of 18F–BPA in animals and humans is different . In addition, metabolic transformation of 18F–BPA and BPA in vivo may also differ. Direct pharmacokinetic comparisons between 18F–BPA and BPA levels in tumors are required during and at the end of BNCT in humans to define early and delayed 18F–BPA imaging times.
The present study had some limitations. Two different tumor types were examined in our study. Our 18F–BPA findings for SCC were consistent with previous studies [28, 31]. However, the characteristics of dynamic 18F–BPA accumulation in radioresistant head and neck carcinomas, such as mucoepidermoid carcinomas and adenoid cystic carcinomas, is unknown . Various intractable cancers that can be treated with BNCT represent a wide spectrum of histopathological backgrounds. Further studies involving more patients, each representing a specific pathological entity, are therefore needed.
Dynamic changes in SUVmax for 18F–BPA uptake in SCC has a washout pattern, while 18F–BPA uptake in MM has a persistent pattern. Dynamic 18F–BPA -PET studies should be performed as part of a human pharmacokinetic study of 18F–BPA and to select appropriate candidates who may benefit from BNCT.
Boron neutron capture therapy
High-performance liquid chromatography
System L amino acid transporter
Positron emission tomography
Regions of interest
Squamous cell carcinoma of the head and neck
Maximum standardized uptake value
Tumor-to-blood pool ratio
Tumor-to–normal tissue accumulation ratio
Henriksson R, Capala J, Michanek A, Lindahl SA, Salford LG, Franzen L, et al. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 2008;88:183-191.
Miyatake S, Kawabata S, Hiramatsu R, Furuse M, Kuroiwa T, Suzuki M. Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases. Radiat Oncol. 2014;9:6.
Suzuki M, Kato I, Aihara T, Hiratsuka J, Yoshimura K, Niimi M, et al. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. J Radiat Res. 2014;55:146–53.
Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, et al. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet. 1989;2:388–9.
Barth RF, Vicente MG, Harling OK, Kiger WS 3rd, Riley KJ, Binns PJ, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol. 2012;7:146.
Herrera MS, Gonzalez SJ, Minsky DM, Kreiner AJ. Evaluation of performance of an accelerator-based BNCT facility for the treatment of different tumor targets. Phys Med. 2013;29:436–46.
Tani H, Kurihara H, Hiroi K, Honda N, Yoshimoto M, Kono Y, et al. Correlation of (18)F-BPA and (18)F-FDG uptake in head and neck cancers. Radiother Oncol. 2014;113:193–7.
Futamura G, Kawabata S, Siba H, Kuroiwa T, Suzuki M, Kondo N, et al. A case of radiation-induced osteosarcoma treated effectively by boron neutron capture therapy. Radiat Oncol. 2014;9:237.
Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med. 1998;39:325–33.
Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Clin Cancer Res. 1998;4:1833–41.
Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, et al. Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot. 2004;61:1069–73.
Nariai T, Ishiwata K, Kimura Y, Inaji M, Momose T, Yamamoto T, et al. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma. Appl Radiat Isot. 2009;67:S348–50.
Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot. 2009;67:S37–42.
Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, et al. FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res. 2014;4:70.
Liberman SJ, Dagrosa A, Jiménez Rebagliati RA, Bonomi MR, Roth BM, Turjanski L, et al. Biodistribution studies of boronophenylalanine-fructose in melanoma and brain tumor patients in Argentina. Appl Radiat Isot. 2004;61:1095–100.
Fukuda H, Honda C, Wadabayashi N, Kobayashi T, Yoshino K, Hiratsuka J, et al. Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. Melanoma Res. 1999;9:75–83.
Ishiwata K, Ido T, Mejia AA, Ichihashi M, Mishima Y. Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-d,l-phenylalanine: a target compound for PET and boron neutron capture therapy. Int J Rad Appl Instrum A. 1991;42:325–8.
Yoshimoto M, Kurihara H, Honda N, Kawai K, Ohe K, Fujii H, et al. Predominant contribution of L-type amino acid transporter to 4-borono-2-(18)F-fluoro-phenylalanine uptake in human glioblastoma cells. Nucl Med Biol. 2013;40:625–9.
Stevens BR. Vertebrate intestine apical membrane mechanisms of organic nutrient transport. Am J Phys. 1992;263:R458–63.
Detta A, Cruickshank GS. L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res. 2009;69:2126–32.
Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15:254–66.
Haase C, Bergmann R, Fuechtner F, Hoepping A, Pietzsch J. Type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18F-fluoro-L-dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo. J Nucl Med. 2007;48:2063–71.
Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human Ltype amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514:291–302.
Kaira K, Sunose Y, Ohshima Y, Ishioka NS, Arakawa K, Ogawa T, et al. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer. 2013;13:482.
Slominski A, Zmijewski MA, Pawelek J. Tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res. 2012;25:14–27.
Wang LW, Wang SJ, Chu PY, Ho CY, Jiang SH, Liu YW, et al. BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua open-pool reactor. Appl Radiat Isot. 2011;69:1803–6.
Aihara T, Hiratsuka J, Morita N, Uno M, Sakurai Y, Maruhashi A, et al. First clinical case of boron neutron capture therapy for head and malignancies using 18F-BPA PET. Head Neck. 2006;28:850–5.
Ariyoshi Y, Shimahara M, Kimura Y, Ito Y, Shimahara T, Miyatake S, et al. Fluorine-18-labeled boronophenylalanine positron emission tomography for oral cancers: qualitative and quantitative analyses of malignant tumors and normal structures in oral and maxillofacial regions. Oncol Lett. 2011;2:423–7.
Kabalka GW, Smith GT, Dyke JP, Reid WS, Longford CP, Roberts TG, et al. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. J Nucl Med. 1997;38:1762–7.
Sakata M, Oda K, Toyohara J, Ishii K, Nariai T, Ishiwata K. Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Ann Nucl Med. 2013;27:285–96.
Kobayashi K, Kurihara H, Watanabe Y, Murakami N, Inaba K, Nakamura S, et al. Vivo spatial correlation between (18)F-BPA and (18)F-FDG uptakes in head and neck cancer. Appl Radiat Isot. 2016;115:138–46.
The authors thank Mr. Takayuki Nanma and the staff of SHI Accelerator Service Ltd. for their technical support. We also thank Ms. Rieko Onoe for her secretarial support. Finally, we thank all the study participants and patients.
This work was supported by the Practical Research for Innovative Cancer Control Program from the Japan Agency for Medical Research and Development, AMED, Number 17ck0106297h0001.
Availability of data and materials
The datasets supporting the conclusion of this article are included within the article.
Ethics approval and consent to participate
This study was reviewed and approved by the National Cancer Center Hospital Research Ethics Review Committee. The committee’s reference number is 2011–165.
Consent for publication
Written informed consent was obtained from all patients for publication of this study. A copy of the written consent forms is available from the Editor-in-Chief of this journal for review.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.